Towards Healthcare

Core Clinical Molecular Diagnostics Companies, Corporate Milestones, Corporate Growth and Development Strategy, Mergers and Acquisitions (M&A), Intellectual Property (IP) Portfolio Management, Market Trends Analysis, Leadership Alignment with Trends

Date: November 2024

Core Clinical Molecular Diagnostics Companies and Competitive Landscape

The core clinical molecular diagnostics market was estimated at US$ 5.3 billion in 2023 and is projected to grow to US$ 14.45 billion by 2034, rising at a compound annual growth rate (CAGR) of 9.54% from 2024 to 2034.

Core Clinical Molecular Diagnostics Market Companies

Top Companies in the Core Clinical Molecular Diagnostics Market

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Amoy Diagnostics
  • Becton, Dickinson and Company
  • Biomerieux
  • Bio-Rad Laboratories
  • CORE Diagnostics
  • Myriad Genetics
  • Qiagen
  • Quest Diagnostics
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific

Latest Announcements by Industry Leaders

Dinesh Chauhan, CEO of CORE Diagnostics, highlighted the economic benefits of high-end diagnostics in an interview in June 2023. He stated that high-end diagnostic testing provides a more accurate and personalized approach to healthcare, resulting in improved patient outcomes and economic benefits for the healthcare system. The increased investments and public-private partnerships drive the opportunity to implement these technologies. He concluded that investing in high-end diagnostics can create a more efficient, effective, and sustainable healthcare system for all.

Recent Developments in the Core Clinical Molecular Diagnostics Market

  • In January 2024, researchers from the Brigham and Women’s Hospital and Wyss Institute developed a molecular assay platform to detect and quantify minute amounts of biomarkers of Parkinson’s disease and related disorders at early stages. The platform has the potential to create early applicable molecular diagnostics, improve clinical trials, and facilitate drug screening.
  • In April 2022, IBM research leveraged next-generation computing technologies, including artificial intelligence, the hybrid cloud, and quantum computing. These advanced technologies were used to streamline and optimize research in the healthcare and life sciences, accelerating the pace by up to ten times and yielding more successful therapeutics and biomarkers.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com